Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free PMN Stock Alerts

Promis Neurosciences (PMN) Competitors

Promis Neurosciences logo
$10.99 -0.08 (-0.72%)
As of 03:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

PMN vs. COEP, FRMM, GOSS, EXOZ, and BTMD

Should you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Coeptis Therapeutics (COEP), Forum Markets (FRMM), Gossamer Bio (GOSS), eXoZymes (EXOZ), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.

How does Promis Neurosciences compare to Coeptis Therapeutics?

Promis Neurosciences (NASDAQ:PMN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Promis Neurosciences presently has a consensus price target of $42.67, suggesting a potential upside of 288.23%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Promis Neurosciences has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 2 mentions for Promis Neurosciences. Coeptis Therapeutics' average media sentiment score of 0.49 beat Promis Neurosciences' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Coeptis Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Promis Neurosciences has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -803.96%. Coeptis Therapeutics' return on equity of -110.89% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
Coeptis Therapeutics -803.96%-110.89%-78.30%

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coeptis Therapeutics has higher revenue and earnings than Promis Neurosciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
Coeptis Therapeutics$1.36M62.79-$11.92M-$2.98N/A

Summary

Coeptis Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to Forum Markets?

Promis Neurosciences (NASDAQ:PMN) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Forum Markets' return on equity of -254.74% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
Forum Markets N/A -254.74%-132.82%

Promis Neurosciences has higher earnings, but lower revenue than Forum Markets. Promis Neurosciences is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
Forum Markets$6.55M15.30-$450.52M-$39.19N/A

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Promis Neurosciences has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Forum Markets has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Promis Neurosciences presently has a consensus price target of $42.67, suggesting a potential upside of 288.23%. Forum Markets has a consensus price target of $5.00, suggesting a potential upside of 1.40%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than Forum Markets.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Forum Markets
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Promis Neurosciences and Promis Neurosciences both had 2 articles in the media. Promis Neurosciences' average media sentiment score of 0.00 equaled Forum Markets'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forum Markets
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Promis Neurosciences and Forum Markets tied by winning 6 of the 12 factors compared between the two stocks.

How does Promis Neurosciences compare to Gossamer Bio?

Promis Neurosciences (NASDAQ:PMN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Promis Neurosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -351.49%. Gossamer Bio's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
Gossamer Bio -351.49%N/A -75.50%

Promis Neurosciences has higher earnings, but lower revenue than Gossamer Bio. Promis Neurosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
Gossamer Bio$48.47M1.63-$170.37M-$0.75N/A

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 7.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Promis Neurosciences has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.

Promis Neurosciences presently has a consensus price target of $42.67, suggesting a potential upside of 288.23%. Gossamer Bio has a consensus price target of $5.43, suggesting a potential upside of 1,515.65%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Promis Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Gossamer Bio
2 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Gossamer Bio had 23 more articles in the media than Promis Neurosciences. MarketBeat recorded 25 mentions for Gossamer Bio and 2 mentions for Promis Neurosciences. Gossamer Bio's average media sentiment score of 0.11 beat Promis Neurosciences' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gossamer Bio
0 Very Positive mention(s)
0 Positive mention(s)
25 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Gossamer Bio beats Promis Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Promis Neurosciences compare to eXoZymes?

Promis Neurosciences (NASDAQ:PMN) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

eXoZymes' return on equity of -147.18% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
eXoZymes N/A -147.18%-104.98%

Promis Neurosciences has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500.

In the previous week, Promis Neurosciences had 2 more articles in the media than eXoZymes. MarketBeat recorded 2 mentions for Promis Neurosciences and 0 mentions for eXoZymes. Promis Neurosciences' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company Overall Sentiment
Promis Neurosciences Neutral
eXoZymes Neutral

eXoZymes is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
eXoZymesN/AN/A-$9.16M-$1.08N/A

Promis Neurosciences presently has a consensus price target of $42.67, suggesting a potential upside of 288.23%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

50.1% of Promis Neurosciences shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Promis Neurosciences and eXoZymes tied by winning 6 of the 12 factors compared between the two stocks.

How does Promis Neurosciences compare to biote?

Promis Neurosciences (NASDAQ:PMN) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

biote has higher revenue and earnings than Promis Neurosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A-$39.72M-$19.00N/A
biote$192.22M0.45$27.05M$0.752.94

Promis Neurosciences presently has a consensus target price of $42.67, indicating a potential upside of 288.23%. biote has a consensus target price of $2.75, indicating a potential upside of 24.60%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Promis Neurosciences is more favorable than biote.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
biote
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

biote has a net margin of 14.07% compared to Promis Neurosciences' net margin of 0.00%. biote's return on equity of -23.41% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -933.63% -295.33%
biote 14.07%-23.41%14.63%

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Promis Neurosciences has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Comparatively, biote has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

In the previous week, biote had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for biote and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.00 equaled biote'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
biote
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

biote beats Promis Neurosciences on 10 of the 14 factors compared between the two stocks.

Get Promis Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PMN vs. The Competition

Export
MetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$98.58M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.5838.9029.0628.47
Price / SalesN/A159.23475.7561.65
Price / CashN/A57.8827.6236.52
Price / Book-18.957.039.716.67
Net Income-$39.72M$23.62M$3.55B$332.53M
7 Day Performance1.29%3.52%1.65%1.98%
1 Month Performance-12.15%7.03%5.54%9.14%
1 Year Performance-31.31%66.41%34.16%39.55%

Promis Neurosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMN
Promis Neurosciences
2.8433 of 5 stars		$10.99
-0.7%		$42.67
+288.2%		N/A$98.58MN/AN/A5
COEP
Coeptis Therapeutics
N/A$15.10
+1.1%		N/AN/A$93.97M$1.36MN/A2
FRMM
Forum Markets
0.2567 of 5 stars		$4.60
+13.9%		$5.00
+8.7%		N/A$93.43M$6.55MN/A7
GOSS
Gossamer Bio
2.5134 of 5 stars		$0.39
+3.3%		$5.43
+1,292.3%		N/A$91.51M$48.47MN/A180
EXOZ
eXoZymes
0.2395 of 5 stars		$10.46
-0.2%		N/AN/A$88.66M$70KN/A29

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PMN) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel